厄贝沙坦联合叶酸对H型高血压患者血压及血浆同型半胱氨酸水平的影响

Effects of Irbesartan Combined with Folic Acid on Blood Pressure and Plasma Homocysteine in Patients with Type H Hypertension

目的:观察厄贝沙坦联合叶酸对H型高血压患者血压及血浆同型半胱氨酸水平的影响。方法:将100例H型高血压患者按随机数字表法均分为对照组和治疗组。对照组患者给予厄贝沙坦150 mg/次,qd,口服;治疗组患者在对照组治疗基础上给予叶酸0.4 mg,qd,口服。两组患者疗程均为3个月。观察两组患者治疗前后肱踝脉搏波传导速度(baPWV)、血浆同型半胱氨酸(Hcy)水平、血压的变化及不良反应发生情况。结果:治疗前,两组患者血浆Hcy、baPWV、舒张压、收缩压比较差异均无统计学意义(P>0.05);治疗后,两组患者血浆Hcy、baPWV、舒张压、收缩压均显著低于同组治疗前,且治疗组低于对照组,两组比较差异均有统计学意义(P<0.05)。两组患者治疗期间均未见明显不良反应发生。结论:厄贝沙坦联合叶酸可降低H型高血压患者血压,改善患者Hcy及baPWV水平。

OBJECTIVE： To observe the effects of irbesartan combined with folic acid on blood pressure and plasma homocysteine in patients with type H hypertension. METHODS： 100 patients with type H hypertension were randomly divided into control group and treatment group; control group was given 150 mg irbesartan orally once a day. Treatment group was given 0.4 mg folic acid orally once a day based on control group. Treatment course of 2 groups lasted for 3 months. The change of baPWV, Hcy , blood pressure and ADR were observed in 2 groups before and after treatment. RESULTS： Hcy , baPWV, diastolic pressure and systolic pressure had no statistical significance between 2 groups before treatment （P〉0.05）. After treatment, Hey, baPWV, diastolic pressure and systolic pressure of 2 groups were significantly lower than before; those of treatment group were lower than those of control group; there was statistical significance （P〈0.05）. No significant ADR was found in 2 groups during treatment. CONCLUSIONS： Irbesartan combined with folic acid can reduce the blood pressure of type H hypertension patients and improve the levels of Hey and baPWV.